{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:01:16Z","timestamp":1793106076524,"version":"4.5.0"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022537","name":"Canadian Society of Endocrinology and Metabolism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024058","name":"Pendopharm","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024058","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.metabol.2025.156335","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T19:05:33Z","timestamp":1750964733000},"page":"156335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Best practice recommendations for the diagnosis and management of hypoparathyroidism"],"prefix":"10.1016","volume":"171","author":[{"given":"Aliya A.","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalal S.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigridur","family":"Bj\u00f6rnsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie E.","family":"Cusano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Ebeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada El Haj","family":"Fuleihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giustina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian A.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayyab","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patty","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mannstadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambrish","family":"Mithal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy D.","family":"Perrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Rayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Rizzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumie","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mishaela R.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L.","family":"Roszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Shrayyef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores M.","family":"Shoback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Sikj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heide","family":"Siggelkow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad","family":"Sfeir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Thakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan","family":"Van Uum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen K.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek Gogas","family":"Yavuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent O.","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajar","family":"AbuAlrob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.metabol.2025.156335_bb0005","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1002\/jbmr.4716","article-title":"Management of Hypoparathyroidism","volume":"37","author":"Khan","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.metabol.2025.156335_bb0010","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-18-0609","article-title":"Standards of care for hypoparathyroidism in adults: a Canadian and international consensus","volume":"180","author":"Khan","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.metabol.2025.156335_bb0015","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41574-024-01075-8","article-title":"Hypoparathyroidism: diagnosis, management and emerging therapies","volume":"21","author":"Khan","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"10.1016\/j.metabol.2025.156335_bb0020","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1002\/jbmr.4673","article-title":"Complications, symptoms, Presurgical predictors in patients with chronic hypoparathyroidism: A systematic review","volume":"37","author":"Yao","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.metabol.2025.156335_bb0025","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMcp0803050","article-title":"Clinical practice","volume":"359","author":"Shoback","year":"2008","journal-title":"Hypoparathyroidism N Engl J Med"},{"issue":"4\u20135","key":"10.1016\/j.metabol.2025.156335_bb0030","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.autrev.2014.01.044","article-title":"Diagnosis and classification of autoimmune parathyroid disease","volume":"13","author":"Betterle","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.metabol.2025.156335_bb0035","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1002\/jbmr.4667","article-title":"Hypoparathyroidism: genetics and diagnosis","volume":"37","author":"Mannstadt","year":"2022","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2025.156335_bb0040","doi-asserted-by":"crossref","unstructured":"Khan AA, Bilezikian JP, Brandi ML, Clarke BL, Gittoes NJ, Pasieka JL, Rejnmark L, Shoback DM, Potts JT, Guyatt GH, Mannstadt M. Evaluation and Management of Hypoparathyroidism Summary Statement and Guidelines from the second international workshop. J Bone Miner Res 2022 Dec;37(12):2568\u201385.","DOI":"10.1002\/jbmr.4691"},{"key":"10.1016\/j.metabol.2025.156335_bb0045","doi-asserted-by":"crossref","unstructured":"Yao L, Li J, Li M, Lin C, Hui X, Tamilselvan D, Kandi M, Sreekanta A, Makhdami N, Ali DS, Dandurand K, Yang K, Bilezikian JP, Brandi ML, Clarke BL, Mannstadt M, Rejnmark L, Khan AA, Guyatt G. Parathyroid hormone therapy for managing chronic hypoparathyroidism: A systematic review and Meta-analysis. J Bone Miner Res 2022 Dec;37(12):2654\u201362.","DOI":"10.1002\/jbmr.4676"},{"key":"10.1016\/j.metabol.2025.156335_bb0050","doi-asserted-by":"crossref","unstructured":"Van Uum S, Shrayyef M, M'Hiri I, Dandurand K, Ali DS, Bilezikian JP, Collins MT, Mannstadt M, Rubin MR, Siggelkow H, Tabacco G, Tay YKD, Vokes T, Winer KK, Yao L, Guyatt G, Rejnmark L, Khan AA. Initial assessment and monitoring of patients with chronic hypoparathyroidism: A systematic current practice survey. J Bone Miner Res 2022 Dec;37(12):2630\u201341.","DOI":"10.1002\/jbmr.4698"},{"key":"10.1016\/j.metabol.2025.156335_bb0055","doi-asserted-by":"crossref","unstructured":"Bjornsdottir S, Ing S, Mitchell DM, Sikjaer T, Underbjerg L, Hassan-Smith Z, Sfeir J, Gittoes NJ, Clarke L BL. Epidemiology and financial burden of adult chronic hypoparathyroidism. J Bone Miner Res 2022 Dec;37(12):2602\u201314.","DOI":"10.1002\/jbmr.4675"},{"key":"10.1016\/j.metabol.2025.156335_bb0060","doi-asserted-by":"crossref","unstructured":"Pasieka JL, Wentworth K, Yeo CT, Cremers S, Dempster D, Fukumoto S, Goswami R, Houillier P, Levine MA, Pasternak JD, Perrier ND, Sitges-Serra A, Shoback DM. Etiology and pathophysiology of hypoparathyroidism: A narrative review. J Bone Miner Res 2022 Dec;37(12):2586\u2013601.","DOI":"10.1002\/jbmr.4714"},{"issue":"2","key":"10.1016\/j.metabol.2025.156335_bb0065","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ecl.2009.01.001","article-title":"Anti-parathyroid and anti-calcium sensing receptor antibodies in autoimmune hypoparathyroidism","volume":"38","author":"Brown","year":"2009","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"9\u201310","key":"10.1016\/j.metabol.2025.156335_bb0070","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1159\/000513768","article-title":"Late recovery of parathyroid function after Total thyroidectomy in children and adults: is there a difference?","volume":"93","author":"de Jong","year":"2020","journal-title":"Horm Res Paediatr"},{"issue":"7","key":"10.1016\/j.metabol.2025.156335_bb0075","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1089\/thy.2014.0500","article-title":"Recovery from permanent hypoparathyroidism after Total thyroidectomy","volume":"25","author":"Kim","year":"2015","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.metabol.2025.156335_bb0080","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1530\/EJE-17-0589","article-title":"Time to parathyroid function recovery in patients with protracted hypoparathyroidism after total thyroidectomy","volume":"178","author":"Villarroya-Marquina","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.metabol.2025.156335_bb0085","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-21-0130","article-title":"Parathyroid hormone of \u22651.6 pmol\/L at 6 months is associated with recovery in \u201clong-term\u201d post-surgical hypoparathyroidism","volume":"11","author":"Arshad","year":"2022","journal-title":"Eur Thyroid J"},{"issue":"11","key":"10.1016\/j.metabol.2025.156335_bb0090","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1210\/jc.2013-2937","article-title":"Recovery of parathyroid hormone secretion and function in postoperative hypoparathyroidism: a case series","volume":"98","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.metabol.2025.156335_bb0095","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/jalm\/jfz010","article-title":"AACC guidance document on biotin interference in laboratory tests","volume":"5","author":"Li","year":"2020","journal-title":"J Appl Lab Med"},{"issue":"8","key":"10.1016\/j.metabol.2025.156335_bb0100","article-title":"Clinically significant lab errors due to vitamin B7 (biotin) supplementation: A case report following a recent FDA warning","volume":"11","author":"Rosner","year":"2019","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.metabol.2025.156335_bb0105","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1001\/jama.2017.13705","article-title":"Association of Biotin Ingestion with Performance of hormone and nonhormone assays in healthy adults","volume":"318","author":"Li","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.metabol.2025.156335_bb0110","doi-asserted-by":"crossref","first-page":"17055","DOI":"10.1038\/nrdp.2017.55","author":"Mannstadt","year":"2017","journal-title":"Hypoparathyroidism Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.metabol.2025.156335_bb0115","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.beem.2018.05.006","article-title":"Hypocalcemic disorders","volume":"32","author":"Bove-Fenderson","year":"2018","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.metabol.2025.156335_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232842","article-title":"Prevalence and complications of nonsurgical hypoparathyroidism in Korea: A nationwide cohort study","volume":"15","author":"Kim","year":"2020","journal-title":"PloS One"},{"issue":"9","key":"10.1016\/j.metabol.2025.156335_bb0125","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/jbmr.2501","article-title":"The epidemiology of nonsurgical hypoparathyroidism in Denmark: A Nationwide case finding study","volume":"30","author":"Underbjerg","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"9","key":"10.1016\/j.metabol.2025.156335_bb0130","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1056\/NEJM198708273170903","article-title":"Gastrointestinal absorption of calcium from milk and calcium salts","volume":"317","author":"Sheikh","year":"1987","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.metabol.2025.156335_bb0135","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJM198904273201703","article-title":"Effect of the time of administration of calcium acetate on phosphorus binding","volume":"320","author":"Schiller","year":"1989","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.metabol.2025.156335_bb0140","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/jbmr.5650030303","article-title":"Dose dependency of calcium absorption: a comparison of calcium carbonate and calcium citrate","volume":"3","author":"Harvey","year":"1988","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.metabol.2025.156335_bb0145","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/ki.1990.7","article-title":"Crystal agglomeration is a major element in calcium oxalate urinary stone formation","volume":"37","author":"Kok","year":"1990","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.metabol.2025.156335_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10586","article-title":"The influence of conventional treatment on symptoms and complaints in patients with chronic postsurgical hypoparathyroidism","volume":"6","author":"Stamm","year":"2022","journal-title":"JBMR Plus"},{"issue":"3","key":"10.1016\/j.metabol.2025.156335_bb0155","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/jbmr.1484","article-title":"Adverse events from calcium supplementation: relationship to errors in myocardial infarction self-reporting in randomized controlled trials of calcium supplementation","volume":"27","author":"Lewis","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2025.156335_bb0160","doi-asserted-by":"crossref","unstructured":"Canat MM, Batman A, D\u00f6nmez \u00c7, K\u00f6stek H, K\u00f6stek M, Kara ZMY, \u00d6zt\u00fcrk FY, Altunta\u015f Y. The effects of adequate dietary calcium intake in patients with hypoparathyroidism non-adherent to treatment: a prospective randomized controlled trial. Rev Assoc Med Bras (1992). 2023;69(11):e20230406.","DOI":"10.1590\/1806-9282.20230406"},{"issue":"2","key":"10.1016\/j.metabol.2025.156335_bb0165","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1359\/jbmr.1998.13.2.168","article-title":"Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women","volume":"13","author":"Riggs","year":"1998","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.metabol.2025.156335_bb0170","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/cen.13955","article-title":"Is calcium supplementation always needed in patients with hypoparathyroidism?","volume":"90","author":"Al-Sharefi","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"10.1016\/j.metabol.2025.156335_bb0175","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1089\/thy.2017.0309","article-title":"American Thyroid Association statement on postoperative hypoparathyroidism: diagnosis, prevention, and management in adults","volume":"28","author":"Orloff","year":"2018","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.metabol.2025.156335_bb0180","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5603\/EP.a2023.0008","article-title":"Clinical efficacy and safety of use of alfacalcidol and calcitriol in daily endocrinological practice","volume":"74","author":"Stuss","year":"2023","journal-title":"Endokrynol Pol"},{"issue":"9","key":"10.1016\/j.metabol.2025.156335_bb0185","article-title":"A comprehensive review on understanding magnesium disorders: pathophysiology, clinical manifestations, and management strategies","volume":"16","author":"Kothari","year":"2024","journal-title":"Cureus"},{"issue":"7","key":"10.1016\/j.metabol.2025.156335_bb0190","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1007\/s00394-022-02916-w","article-title":"MaGNet global magnesium project (MaGNet). Recommendation on an updated standardization of serum magnesium reference ranges","volume":"61","author":"Rosanoff","year":"2022","journal-title":"Eur J Nutr"},{"issue":"4","key":"10.1016\/j.metabol.2025.156335_bb0195","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jaad.2017.11.042","article-title":"Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark","volume":"78","author":"Pedersen","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.metabol.2025.156335_bb0200","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/j.jrn.2012.12.003","article-title":"The prevalence of phosphorus-containing food additives in top-selling foods in grocery stores","volume":"23","author":"Le\u00f3n","year":"2013","journal-title":"J Ren Nutr"},{"issue":"4","key":"10.1016\/j.metabol.2025.156335_bb0205","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1007\/s12325-021-01658-1","article-title":"Risk of chronic kidney disease and estimated glomerular filtration rate decline in patients with chronic hypoparathyroidism: A retrospective cohort study","volume":"38","author":"Gosmanova","year":"2021","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.metabol.2025.156335_bb0210","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1007\/s12325-021-01649-2","article-title":"Risk of nephrolithiasis and Nephrocalcinosis in patients with chronic hypoparathyroidism: A retrospective cohort study","volume":"38","author":"Ketteler","year":"2021","journal-title":"Adv Ther"},{"issue":"6","key":"10.1016\/j.metabol.2025.156335_bb0215","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1365-2265.2011.04142.x","article-title":"Activating mutations in the calcium-sensing receptor: genetic and clinical spectrum in 25 patients with autosomal dominant hypocalcaemia - a German survey","volume":"75","author":"Raue","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10.1016\/j.metabol.2025.156335_bb0220","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12020-023-03443-2","article-title":"Impairments in quality of life and predictors of symptom burden in patients with hypoparathyroidism: results from a population-based survey","volume":"82","author":"B\u00fcttner","year":"2023","journal-title":"Endocrine"},{"issue":"7","key":"10.1016\/j.metabol.2025.156335_bb0225","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jbmr\/zjae063","article-title":"Hypoparathyroidism: changes in brain structure, cognitive impairment, and reduced quality of life","volume":"39","author":"Sikjaer","year":"2024","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2025.156335_bb0230","doi-asserted-by":"crossref","unstructured":"Anaforoglu I, Sancak S, Akbas EM, Oruk GG, Canat M, Tezcan KA, Uc ZA, Gorar S, Duman GC, Yaylali GF, Y\u0131lmaz M, Bilir BE, Bozoglan H, Akbaba G, Tuna MM, Akcay S, Tuzun D, Bagir GS, Haydardedeoglu FE, Elbuken G, Yorulmaz G, Celik O, Topbas M. Effects of treatment adherence on quality of life in Hypoparathyroid patients. Exp Clin Endocrinol Diabetes 2021 Dec;129(12):918\u201325.","DOI":"10.1055\/a-1400-2668"},{"issue":"1","key":"10.1016\/j.metabol.2025.156335_bb0235","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11657-022-01066-0","article-title":"Assessment of calcium and vitamin D medications adherence in patients with hypoparathyroidism after thyroidectomy","volume":"17","author":"Bilginer","year":"2022","journal-title":"Arch Osteoporos"},{"issue":"10","key":"10.1016\/j.metabol.2025.156335_bb0240","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/jbmr.483","article-title":"Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research","volume":"26","author":"Bilezikian","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.metabol.2025.156335_bb0245","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1152\/physrev.00027.2015","article-title":"Maternal mineral and Bone metabolism during pregnancy, lactation, and post-weaning recovery","volume":"96","author":"Kovacs","year":"2016","journal-title":"Physiol Rev"},{"issue":"9","key":"10.1016\/j.metabol.2025.156335_bb0250","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/jbmr.1925","article-title":"Upregulation of calcitriol during pregnancy and skeletal recovery after lactation do not require parathyroid hormone","volume":"28","author":"Kirby","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.metabol.2025.156335_bb0255","doi-asserted-by":"crossref","first-page":"R37","DOI":"10.1530\/EJE-18-0541","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: hypoparathyroidism in pregnancy: review and evidence-based recommendations for management","volume":"180","author":"Khan","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"4817","key":"10.1016\/j.metabol.2025.156335_bb0260","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1126\/science.3616618","article-title":"A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression","volume":"237","author":"Suva","year":"1987","journal-title":"Science"},{"issue":"5034","key":"10.1016\/j.metabol.2025.156335_bb0265","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1126\/science.1658941","article-title":"A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide","volume":"254","author":"J\u00fcppner","year":"1991","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.metabol.2025.156335_bb0270","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/archpedi.1979.02130010073013","article-title":"Postmortem findings in two cases","volume":"133","author":"Stuart","year":"1979","journal-title":"Am J Dis Child"},{"issue":"5","key":"10.1016\/j.metabol.2025.156335_bb0275","first-page":"305","article-title":"Neonatal hyperparathyroidism secondary to maternal hypoparathyroidism (author\u2019s transl)","volume":"37","author":"Vidailhet","year":"1980","journal-title":"Arch Fr Pediatr"},{"issue":"6500","key":"10.1016\/j.metabol.2025.156335_bb0280","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/bmj.291.6500.955","article-title":"Prolonged hypoparathyroidism presenting eventually as second trimester abortion","volume":"291","author":"Eastell","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"11","key":"10.1016\/j.metabol.2025.156335_bb0285","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1210\/clinem\/dgab503","article-title":"Women with chronic hypoparathyroidism have low risk of adverse pregnancy outcomes","volume":"106","author":"Bj\u00f6rnsdottir","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.metabol.2025.156335_bb0290","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/s13023-021-02053-3","article-title":"Hypoparathyroidism and pseudohypoparathyroidism in pregnancy: an Italian retrospective observational study","volume":"16","author":"Marcucci","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.metabol.2025.156335_bb0295","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-21-1044","article-title":"European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE educational program of parathyroid disorders","volume":"186","author":"Bollerslev","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2025.156335_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.115977","article-title":"Therapy with PTH 1-34 or calcitriol and calcium in diverse etiologies of hypoparathyroidism over 27 years at a single tertiary care center","volume":"149","author":"Winer","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2025.156335_bb0305","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jpeds.2018.08.010","article-title":"Long-term parathyroid hormone 1-34 replacement therapy in children with hypoparathyroidism","volume":"203","author":"Winer","year":"2018","journal-title":"J Pediatr"},{"issue":"13","key":"10.1016\/j.metabol.2025.156335_bb0310","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.88782","article-title":"Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy","volume":"1","author":"Ferre","year":"2016","journal-title":"JCI Insight"},{"issue":"9","key":"10.1016\/j.metabol.2025.156335_bb0315","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1210\/jc.2007-2552","article-title":"Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism","volume":"93","author":"Winer","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.metabol.2025.156335_bb0320","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1210\/jc.2009-2464","article-title":"Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium","volume":"95","author":"Winer","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.metabol.2025.156335_bb0325","first-page":"391","article-title":"Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism","volume":"97","author":"Winer","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.metabol.2025.156335_bb0330","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jpeds.2014.04.060","article-title":"Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism","volume":"165","author":"Winer","year":"2014","journal-title":"J Pediatr"},{"key":"10.1016\/j.metabol.2025.156335_bb0335","doi-asserted-by":"crossref","unstructured":"Linglart A, Rothenbuhler A, Gueorgieva I, Lucchini P, Silve C, Bougn\u00e8res P. Long-term results of continuous subcutaneous recombinant PTH (1-34) infusion in children with refractory hypoparathyroidism. J Clin Endocrinol Metab 2011 Nov;96(11):3308\u201312.","DOI":"10.1210\/jc.2011-1359"},{"issue":"4","key":"10.1016\/j.metabol.2025.156335_bb0340","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000479867","article-title":"Continuous subcutaneous recombinant parathyroid hormone (1-34) infusion in the Management of Childhood Hypoparathyroidism Associated with malabsorption","volume":"89","author":"Saraff","year":"2018","journal-title":"Horm Res Paediatr"},{"issue":"6","key":"10.1016\/j.metabol.2025.156335_bb0345","article-title":"Initiation of continuous rhPTH infusion with insulin pump in an inpatient setting","volume":"1","author":"Lindsay Mart","year":"2023","journal-title":"JCEM Case Rep"},{"issue":"8","key":"10.1016\/j.metabol.2025.156335_bb0355","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/jbmr.4016","article-title":"A randomized double-blind placebo-controlled first-in-human phase 1 trial of TransCon PTH in healthy adults","volume":"35","author":"Karpf","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"11","key":"10.1016\/j.metabol.2025.156335_bb0360","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/jbmr.3824","article-title":"Design and preclinical development of TransCon PTH, an investigational sustained-release PTH replacement therapy for hypoparathyroidism","volume":"34","author":"Holten-Andersen","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"9","key":"10.1016\/j.metabol.2025.156335_bb0365","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1210\/jc.2002-021736","article-title":"Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium","volume":"88","author":"Winer","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.metabol.2025.156335_bb0370","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/jbmr.3480","article-title":"Hypocitraturia is an untoward side effect of synthetic human parathyroid hormone (hPTH) 1-34 therapy in hypoparathyroidism that may increase renal morbidity","volume":"33","author":"Gafni","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.metabol.2025.156335_bb0375","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1210\/jc.2017-01555","article-title":"PTH(1-34) for surgical hypoparathyroidism: a 2-year prospective, open-label investigation of efficacy and quality of life","volume":"103","author":"Palermo","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"1\u20132","key":"10.1016\/j.metabol.2025.156335_bb0380","first-page":"53","article-title":"Teriparatide (rhPTH) treatment in children with syndromic hypoparathyroidism","volume":"27","author":"Matarazzo","year":"2014","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.metabol.2025.156335_bb0385","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s12020-019-02128-z","article-title":"Teriparatide (rhPTH 1-34) treatment in the pediatric age: long-term efficacy and safety data in a cohort with genetic hypoparathyroidism","volume":"67","author":"Tuli","year":"2020","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.metabol.2025.156335_bb0390","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/cen.12944","article-title":"Diverse genetic aetiologies and clinical outcomes of paediatric hypoparathyroidism","volume":"83","author":"Kim","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.metabol.2025.156335_bb0395","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study","volume":"1","author":"Mannstadt","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.metabol.2025.156335_bb0400","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1210\/jc.2019-00893","article-title":"Therapy of hypoparathyroidism with rhPTH(1-84): a prospective, 8-year investigation of efficacy and safety","volume":"104","author":"Tay","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.metabol.2025.156335_bb0405","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","article-title":"The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study","volume":"26","author":"Sikjaer","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"11","key":"10.1016\/j.metabol.2025.156335_bb0410","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1210\/jc.2019-01010","article-title":"Safety and efficacy of 5 years of treatment with recombinant human parathyroid hormone in adults with hypoparathyroidism","volume":"104","author":"Mannstadt","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.metabol.2025.156335_bb0415","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/jbmr.4005","article-title":"Changes in skeletal microstructure through four continuous years of rhPTH(1-84) therapy in hypoparathyroidism","volume":"35","author":"Cusano","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"7","key":"10.1016\/j.metabol.2025.156335_bb0420","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1210\/jc.2015-4135","article-title":"Therapy of hypoparathyroidism with PTH(1-84): A prospective six year investigation of efficacy and safety","volume":"101","author":"Rubin","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.metabol.2025.156335_bb0425","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1210\/clinem\/dgab577","article-title":"PaTH forward: A randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism","volume":"107","author":"Khan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.metabol.2025.156335_bb0430","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/jbmr.4726","article-title":"Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial","volume":"38","author":"Khan","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.metabol.2025.156335_bb0435","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1007\/s12325-024-02843-8","article-title":"Palopegteriparatide treatment improves renal function in adults with chronic hypoparathyroidism: 1-year results from the phase 3 PaTHway trial","volume":"41","author":"Rejnmark","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.metabol.2025.156335_bb0440","series-title":"Palopegteriparatide Improves Skeletal Dynamics in Adults With Chronic Hypoparathyroidism: 3-Year Results From the Phase 2 PaTH Forward Trial. Oral presentation at ASBMR 2024 Annual Meeting","author":"Rubin","year":"2024"},{"issue":"7","key":"10.1016\/j.metabol.2025.156335_bb0445","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/jbmr.2811","article-title":"Pharmacodynamic actions of a long-acting PTH analog (LA-PTH) in thyroparathyroidectomized (TPTX) rats and normal monkeys","volume":"31","author":"Shimizu","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"9","key":"10.1016\/j.metabol.2025.156335_bb0450","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1210\/clinem\/dgae121","article-title":"An open-label phase 2 study of eneboparatide, a novel PTH receptor 1 agonist","volume":"109","author":"Takacs","year":"2024","journal-title":"Hypoparathyroidism J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2025.156335_bb0455","series-title":"A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Eneboparatide (AZP-3601), a Parathyroid Hormone Receptor Agonist, in Patients With Chronic Hypoparathyroidism (CALYPSO) [Internet]","author":"Amolyt Pharma","year":"2024"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2025.156335_bb0460","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.2215\/CJN.05910809","article-title":"Calcium metabolism in health and disease","volume":"5","author":"Peacock","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.metabol.2025.156335_bb0465","first-page":"2366","article-title":"Calcium-regulated renal calcium handling in healthy men: relationship to sodium handling","volume":"83","author":"El-Hajj Fuleihan","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.metabol.2025.156335_bb0470","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/ng1194-303","article-title":"Autosomal dominant hypocalcaemia caused by a ca(2+)-sensing receptor gene mutation","volume":"8","author":"Pollak","year":"1994","journal-title":"Nat Genet"},{"key":"10.1016\/j.metabol.2025.156335_bb0475","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3389\/fphys.2016.00458","article-title":"Autosomal dominant hypocalcemia (hypoparathyroidism) types 1 and 2","volume":"7","author":"Roszko","year":"2016","journal-title":"Front Physiol"},{"issue":"10","key":"10.1016\/j.metabol.2025.156335_bb0480","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/jbmr.4659","article-title":"Autosomal dominant hypocalcemia type 1: a systematic review","volume":"37","author":"Roszko","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"9","key":"10.1016\/j.metabol.2025.156335_bb0485","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/jbmr.3747","article-title":"Treatment of autosomal dominant hypocalcemia type 1 with the Calcilytic NPSP795 (SHP635)","volume":"34","author":"Roberts","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"13","key":"10.1016\/j.metabol.2025.156335_bb0490","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1056\/NEJMc2302708","article-title":"Efficacy and safety of encaleret in autosomal dominant hypocalcemia type 1","volume":"389","author":"Gafni","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.metabol.2025.156335_bb0495","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1210\/clinem\/dgae808","article-title":"MBX 2109, A once-weekly parathyroid hormone replacement therapy prodrug: phase 1, first-in-human","volume":"110","author":"Carney","year":"2025","journal-title":"Randomized Trial J Clin Endocrinol Metab"},{"issue":"Supplement_1","key":"10.1016\/j.metabol.2025.156335_bb0500","article-title":"9263 characterization of A novel Oral small molecule PTH1R agonist: proof of concept for An alternative to injectable peptide-based therapy for hypoparathyroidism","volume":"8","author":"Zhang","year":"2024","journal-title":"Journal of the Endocrine Society"},{"issue":"4","key":"10.1016\/j.metabol.2025.156335_bb0505","doi-asserted-by":"crossref","first-page":"418","DOI":"10.4300\/JGME-D-22-00481.1","article-title":"Narrative reviews in medical education: key steps for researchers","volume":"14","author":"Sukhera","year":"2022","journal-title":"J Grad Med Educ"},{"key":"10.1016\/j.metabol.2025.156335_bb0510","series-title":"The Parathyroids","first-page":"761","article-title":"Chapter 53 - clinical manifestations of hypoparathyroidism","author":"Mannstadt","year":"2015"},{"issue":"2","key":"10.1016\/j.metabol.2025.156335_bb0515","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s12020-021-02629-w","article-title":"Canadian national hypoparathyroidism registry: an overview of hypoparathyroidism in Canada","volume":"72","author":"Khan","year":"2021","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.metabol.2025.156335_bb0520","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2265.2012.04353.x","article-title":"Prevalence and progression of basal ganglia calcification and its pathogenic mechanism in patients with idiopathic hypoparathyroidism","volume":"77","author":"Goswami","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"10.1016\/j.metabol.2025.156335_bb0525","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10368","article-title":"Quantification of symptom load by a disease-specific questionnaire HPQ 28 and analysis of associated biochemical parameters in patients with postsurgical hypoparathyroidism","volume":"4","author":"Wilde","year":"2020","journal-title":"JBMR Plus"},{"key":"10.1016\/j.metabol.2025.156335_bb0530","article-title":"Cognitive function in individuals with chronic hypoparathyroidism - a prospective observational study","author":"Tmava-Berisha","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.metabol.2025.156335_bb0535","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00198-025-07410-7","article-title":"Skeletal health status among patients with chronic hypoparathyroidism: results from the Canadian National Hypoparathyroidism Registry (CNHR)","volume":"36","author":"Khan","year":"2025","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.metabol.2025.156335_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2024.117274","article-title":"Predictors of lumbar spine trabecular bone score in women with postsurgical hypoparathyroidism","volume":"190","author":"Carvalho","year":"2025","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.metabol.2025.156335_bb0545","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/jbmr\/zjaf061","article-title":"Increased risk of vertebral fractures and reduced risk of femur fractures in patients with chronic hypoparathyroidism: a Nationwide cohort study in Sweden","volume":"40","author":"Bj\u00f6rnsdottir","year":"2025","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2025.156335_bb0550","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.948435","article-title":"Morphometric vertebral fracture risk in women with postsurgical hypoparathyroidism","volume":"13","author":"d\u2019Alva","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"10.1016\/j.metabol.2025.156335_bb0555","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.3390\/jcm10071378","article-title":"Hypoparathyroidism in pregnancy and lactation: current approach to diagnosis and management","volume":"10","author":"Ali","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.metabol.2025.156335_bb0560","series-title":"Basic medical endocrinology","first-page":"197","article-title":"Chapter 10 - hormonal regulation of calcium balance","author":"Goodman","year":"2009"},{"issue":"1","key":"10.1016\/j.metabol.2025.156335_bb0565","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41574-018-0115-0","article-title":"The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases","volume":"15","author":"Hannan","year":"2018","journal-title":"Nat Rev Endocrinol"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049525002045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049525002045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T16:31:03Z","timestamp":1754929863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049525002045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":112,"alternative-id":["S0026049525002045"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2025.156335","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Best practice recommendations for the diagnosis and management of hypoparathyroidism","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2025.156335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"156335"}}